Alnylam Pharmaceuticals, Inc.
RNAi patent granted by the European Patent Office
Published in Law and Health Weekly, July 16th, 2005
Alnylam Pharmaceuticals, Inc., (ALNY), an RNAi therapeutics company, and Cancer Research Technology Limited (CRT) announced that notice of grant has been received from the European Patent Office (EPO) for an important new RNAi patent entitled "Inhibiting gene expression with double-stranded RNA" to which Alnylam has exclusive therapeutic rights, through its existing license agreement with CRT.
The newly granted patent includes broad claims covering therapeutic use of double-stranded RNA expressed from endogenous templates or expression vectors to mediate RNA interference (RNAi).
This is the first of multiple European patents expected to stem from the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Albert Schweitzer Hospital, Dordrecht
Prolonged skin staining after intradermal use of patent blue purported - Australia EpiTan Limited
Endpoint trial of Melanotan begins in Sydney - CytRx Corporation
Commission releases biopharmaceutical company from conflict of interest inquiry - Elan Corp., plc
Neuroscience-based biotech settles legal action with former employee - Enzo Biochem, Inc.
Company acquires rights to orphan drug candidate for uveitis - Johns Hopkins Medical Institutions
Stem cells grown in lab mirror normal developmental steps - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
